-

VectorBuilder to Present on Advancing AAV-Based Therapies at ARVO 2026

CHICAGO--(BUSINESS WIRE)--VectorBuilder, a global leader in gene delivery technologies and CDMO solutions, will participate in the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, taking place in Denver, Colorado, from May 3 to 7.

VectorBuilder to Highlight Persistent Challenges Limiting AAV Therapy Performance at ARVO Annual Meeting 2026

Share

As AAV-based gene therapies continue to gain traction in ophthalmology, attention is shifting toward the underlying factors that influence consistency, durability, and clinical performance. Variability in vector design and production remains a persistent challenge, particularly as programs move beyond early-stage success into broader clinical application.

At this year’s meeting, VectorBuilder’s CDMO for Global Operations, Alan Griffith, will present “Seeing Old Problems in a New Light: Unlocking the Full Potential of AAV-Based Therapies.” During the session, he will address longstanding challenges in AAV development and their impact on therapeutic performance and scalability. The presentation will explore how vector design considerations influence consistency and downstream outcomes, particularly as programs advance toward clinical application.

“AAV has become a cornerstone of gene therapy development, particularly in ophthalmology, but its full potential depends on how consistently it can be designed and produced,” said Griffith. “Revisiting long-standing assumptions around vector design is essential to improving reliability and translating early success into broader clinical impact.”

The ARVO Annual Meeting brings together researchers and clinicians from around the world to explore advances in vision science and translational ophthalmology, with a strong focus on therapies targeting retinal and ocular disease.

VectorBuilder will be available during ARVO for meetings with media, partners, and attendees interested in developments in AAV vector design, gene delivery technologies, and integrated CDMO capabilities.

About VectorBuilder

VectorBuilder is a global leader in gene delivery technologies. As a trusted partner in thousands of labs and biotech/pharma companies around the world, VectorBuilder is a one-stop shop for the design, development, and optimization of gene delivery solutions from basic research to clinical applications. Its award-winning Vector Design Studio is a transformative innovation that allows researchers to easily design and order custom vectors online, freeing them from the tedious work of cloning and packaging vectors in the lab. The global company boasts high-throughput vector production capacity, vast vector and component inventories, one-on-one CRO solutions that include advanced AAV capsid engineering capabilities, and state-of-the-art GMP manufacturing facilities. With leading R&D and CDMO capabilities, the VectorBuilder team strives to provide the most effective gene-delivery solutions and develop innovative tools for life sciences research and genetic medicine.

Contacts

More News From VectorBuilder

2026 BioTech Breakthrough Honors VectorBuilder With “Overall CGT Solution Provider of the Year”

CHICAGO--(BUSINESS WIRE)--VectorBuilder, a global leader in gene delivery technologies, today announced it has been named “Overall CGT Solution Provider of the Year” in the sixth annual BioTech Breakthrough Awards, recognizing innovation across the global life sciences and biotechnology industries. VectorBuilder integrates vector design, cloning, packaging, optimization, process development, and GMP manufacturing within one organization. Through its online Vector Studio, researchers can design...

VectorBuilder to Present at the ASHG 2026 Annual Meeting

CHICAGO--(BUSINESS WIRE)--VectorBuilder today announced that it will present and exhibit at the American Society of Human Genetics (ASHG) 2026 Annual Meeting, taking place October 20–24 in Montréal, Canada, and that Dr. Morgan Dwyer will present during the meeting. Dwyer will present “Development of a Compact Bidirectional Promoter for Coordinated Multi-Gene Expression” as part of the Translational and Technological Advances in Genetic Therapies session on Saturday, October 24 at 8:45 a.m. The...

VectorBuilder and Lir Therapeutics Partner to Advance AAV Capsids Designed for Clinical Success

CHICAGO--(BUSINESS WIRE)--VectorBuilder, a global leader in gene delivery technologies, and Lir Therapeutics, a company pushing the boundaries of vector engineering with AI, today announced a strategic collaboration to develop adeno-associated virus (AAV) capsids designed not only for strong biological performance, but also for the manufacturability and scalability required to bring gene therapies into the clinic. The partnership brings together VectorBuilder’s expertise in AAV discovery, capsi...
Back to Newsroom